During the past decade, Schwarzwald-Baar Klinikum/VS GmbH; Onkologie/Hämatologie/Infektologie conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 3 clinical trials were completed, i.e. on average, 60% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Schwarzwald-Baar Klinikum/VS GmbH; Onkologie/Hämatologie/Infektologie" #1 collaborator was "Bristol-Myers Squibb" with 1 trials as a collaborator, "German High-Grade Non-Hodgkin's Lymphoma Study Group" with 1 trials as a collaborator, "Lymphoma Study Association" with 1 trials as a collaborator, "Spectrum Pharmaceuticals, Inc" with 1 trials as a collaborator and "University of Leipzig" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Schwarzwald-Baar Klinikum/VS GmbH; Onkologie/Hämatologie/Infektologie" are "Non-Small Cell Lung Cancer" (2 trials), "CD20+ Aggressive B-Cell Lymphoma" (1 trials), "Carcinoma, Non-Squamous Non-Small Cell Lung" (1 trials), "Lymphoma, Non-Hodgkin" (1 trials) and "Multiple Myeloma" (1 trials). Many other conditions were trialed in "Schwarzwald-Baar Klinikum/VS GmbH; Onkologie/Hämatologie/Infektologie" in a lesser frequency.

Most popular intervention types in "Schwarzwald-Baar Klinikum/VS GmbH; Onkologie/Hämatologie/Infektologie" are "Drug" (7 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Carboplatin" (2 trials), "Nab-Paclitaxel" (2 trials), "Atezolizumab" (1 trials), "Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody" (1 trials) and "Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody" (1 trials). Other intervention names were less common.

The vast majority of trials in "Schwarzwald-Baar Klinikum/VS GmbH; Onkologie/Hämatologie/Infektologie" are 7 trials for "All" genders.

Currently, there are NaN active trials in "Schwarzwald-Baar Klinikum/VS GmbH; Onkologie/Hämatologie/Infektologie". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Schwarzwald-Baar Klinikum/VS GmbH; Onkologie/Hämatologie/Infektologie, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Schwarzwald-Baar Klinikum/VS GmbH; Onkologie/Hämatologie/Infektologie, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".